Efficacy of Larotrectinib (LOXO-101) in Adult and Pediatric TRK Fusion Cancers

Efficacy of Larotrectinib (LOXO-101) in Adult and Pediatric TRK Fusion Cancers

AnnualMeeting2017

2 years
828 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
David Michael Hyman, MD of Memorial Sloan-Kettering gives an overview his presentation, which focuses on the efficacy of larotrectinib (LOXO-101) in adult and pediatric TRK fusion cancers at the 2017 ASCO Annual Meeting in Chicago, IL.

LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Up Next Autoplay